Skip to main content
. 2024 Feb 24;14(5):488. doi: 10.3390/diagnostics14050488

Figure 4.

Figure 4

Assessment of QfusionTM assays’ performance utilizing clinical samples. (a) Results from the analysis of 57 FFPE lung cancer patient samples using the QfusionTM ALK, RET, or ROS1 fusion detection assay. The data reveals the identification of one patient with ALK and RET fusions and one patient with ROS1 fusion. (b) Validation of distinct fusion events through singleplex RT-qPCR. The identified ALK fusions included EML4-ALK V1/V7, while the RET fusion involved CCDC6-RET. Additionally, a single ROS1 fusion event, CD74-ROS1, was confirmed.